DK155936B - Analogifremgangsmaade til fremstilling af 2-amino-3-(halogenbenzoyl)-methylphenyleddikesyrer eller alkylestere eller metalsalte deraf - Google Patents
Analogifremgangsmaade til fremstilling af 2-amino-3-(halogenbenzoyl)-methylphenyleddikesyrer eller alkylestere eller metalsalte deraf Download PDFInfo
- Publication number
- DK155936B DK155936B DK067382A DK67382A DK155936B DK 155936 B DK155936 B DK 155936B DK 067382 A DK067382 A DK 067382A DK 67382 A DK67382 A DK 67382A DK 155936 B DK155936 B DK 155936B
- Authority
- DK
- Denmark
- Prior art keywords
- acid
- amino
- preparation
- formula
- metal salts
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 16
- 239000002253 acid Substances 0.000 title claims description 13
- 238000000034 method Methods 0.000 title claims description 12
- 229910052751 metal Inorganic materials 0.000 title claims description 9
- 239000002184 metal Substances 0.000 title claims description 9
- 150000003839 salts Chemical class 0.000 title claims description 8
- 150000007513 acids Chemical class 0.000 title claims description 3
- 125000005907 alkyl ester group Chemical class 0.000 claims description 5
- 150000001768 cations Chemical class 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000001350 alkyl halides Chemical class 0.000 claims description 2
- 239000003637 basic solution Substances 0.000 claims description 2
- 125000006331 halo benzoyl group Chemical group 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 19
- 239000000203 mixture Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 14
- 239000002775 capsule Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 230000000622 irritating effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 2
- UFZNNOHNAOYQQP-UHFFFAOYSA-N 7-phenacyl-1,3-dihydroindol-2-one Chemical compound C=1C=CC=2CC(=O)NC=2C=1CC(=O)C1=CC=CC=C1 UFZNNOHNAOYQQP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- LSSUHHIPNSAMIU-UHFFFAOYSA-N C(C)(=O)OC1=C(C(=CC(=C1)C)C(C1=CC=C(C=C1)Cl)=O)N.[Na] Chemical compound C(C)(=O)OC1=C(C(=CC(=C1)C)C(C1=CC=C(C=C1)Cl)=O)N.[Na] LSSUHHIPNSAMIU-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- YPGCWEMNNLXISK-UHFFFAOYSA-N hydratropic acid Chemical class OC(=O)C(C)C1=CC=CC=C1 YPGCWEMNNLXISK-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- -1 sodium-2-amino-3-benzoylphenyl acetate Chemical compound 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- YBNYPWAZNIKXNI-UHFFFAOYSA-N 1-(4-chlorobenzoyl)-6-methyl-3H-indol-2-one Chemical compound ClC1=CC=C(C(=O)N2C(CC3=CC=C(C=C23)C)=O)C=C1 YBNYPWAZNIKXNI-UHFFFAOYSA-N 0.000 description 1
- YVKSMFUEDUPYIF-UHFFFAOYSA-N 3-oxo-2,3-diphenylpropanoic acid Chemical class C=1C=CC=CC=1C(C(=O)O)C(=O)C1=CC=CC=C1 YVKSMFUEDUPYIF-UHFFFAOYSA-N 0.000 description 1
- NDUYSRWSHUHRGD-UHFFFAOYSA-N 4-methyl-7-(2,3,5-trichlorobenzoyl)-1,3-dihydroindol-2-one Chemical compound ClC1=C(C(=O)C=2C=CC(=C3CC(NC23)=O)C)C=C(C=C1Cl)Cl NDUYSRWSHUHRGD-UHFFFAOYSA-N 0.000 description 1
- ROYCPOZLJYCXIZ-UHFFFAOYSA-N 7-(2,4-dichlorobenzoyl)-5-methyl-1,3-dihydroindol-2-one Chemical compound ClC1=C(C(=O)C=2C=C(C=C3CC(NC23)=O)C)C=CC(=C1)Cl ROYCPOZLJYCXIZ-UHFFFAOYSA-N 0.000 description 1
- WQRSNHWRHMQPLP-UHFFFAOYSA-N 7-(4-fluorobenzoyl)-5-methyl-1,3-dihydroindol-2-one Chemical compound C=1C(C)=CC=2CC(=O)NC=2C=1C(=O)C1=CC=C(F)C=C1 WQRSNHWRHMQPLP-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- IYIZHXIAABPNIM-UHFFFAOYSA-N C(C)(=O)OC1=C(C(=CC(=C1)C)C(C1=C(C=C(C=C1)Cl)Cl)=O)N.[Na] Chemical compound C(C)(=O)OC1=C(C(=CC(=C1)C)C(C1=C(C=C(C=C1)Cl)Cl)=O)N.[Na] IYIZHXIAABPNIM-UHFFFAOYSA-N 0.000 description 1
- NQPUKSBYJQZIBE-UHFFFAOYSA-N C(C)(=O)OC1=C(C(=CC=C1C)C(C1=C(C(=CC(=C1)Cl)Cl)Cl)=O)N.[Na] Chemical compound C(C)(=O)OC1=C(C(=CC=C1C)C(C1=C(C(=CC(=C1)Cl)Cl)Cl)=O)N.[Na] NQPUKSBYJQZIBE-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- GQSXJNIEJJXXBZ-UHFFFAOYSA-N O.C(C)(=O)OC1=C(C(=CC(=C1)C)C(C1=CC=C(C=C1)F)=O)N.[Na] Chemical compound O.C(C)(=O)OC1=C(C(=CC(=C1)C)C(C1=CC=C(C=C1)F)=O)N.[Na] GQSXJNIEJJXXBZ-UHFFFAOYSA-N 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- SOYCMDCMZDHQFP-UHFFFAOYSA-N amfenac Chemical class NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=CC=C1 SOYCMDCMZDHQFP-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C1/00—Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C57/32—Phenylacetic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Description
i
DK 155936 B
Den foreliggende opfindelse angår en analogifrem-gangsmåde til fremstilling af hidtil ukendte 2-amino-3-(halo-genbenzoyl)-methylphenyleddikesyrer eller alkylestere eller metalsalte deraf.
5 Visse 2-amino-3-(5 og 6)benzoylphenyleddikesyrer med forskellige substituenter ved benzyl- og phenylgruppen og metoder til fremstilling og anvendelse af disse er beskrevet i US-patentskrift nr. 4.045.576. Forbindelserne ifølge dette patentskrift er ikke methylphenyleddikesyrer eller derivater 10 deraf.
I US-patentskrift nr. 4.221.716 beskrives en fremgangsmåde til fremstilling af 7-acylindolin-2-oner, der er mellemprodukter ved fremstillingen af forbindelserne ifølge den foreliggende opfindelse.
15 Opfindelsen angår nærmere bestemt en analogifrem
gangsmåde til fremstilling af 2-amino-3-(halogenbenzoyl)--methylphenyleddikesyrer eller alkylestere eller metalsalte med formlen I
20 ClfeCOOR
CH3 rC_) I
Lo <« ” ^ (*>n hvori R er valgt blandt hydrogen, lavere alkyl og en farmaceu- 30 tisk acceptabel metalkation, Y betyder halogen, og n betyder et helt tal på l til 3, og fremgangsmåden er ejendommelig ved, at en 7-benzoylmethyl-indolin-2-on med formlen
DK 155936 B
2 Μδη
0=C H
5 JL
hvori 10 Y og n har den ovenfor angivne betydning, hydrolyseres i vandig basisk opløsning til dannelse af et salt af en syre med formlen I, der eventuelt omsættes med en syre til dannelse af en fri syre med formlen I, hvorefter denne frie syre eventuelt omdannes til et metalsalt deraf, 15 som eventuelt omsættes i et egnet opløsningsmiddel med et lavere alkylhalogenid til dannelse af en alkylester med formlen I.
De her omhandlede, hidtil ukendte forbindelser har værdifulde farmakologiske egenskaber og er anvendelige som 20 farmaceutiske midler. Forbindelserne udviser fremragende antiinflammatorisk og analgetisk virkning hos varmblodede dyr med minimal mave-tarm-toksicitet.
Ved definitionen af symboler i formlerne her og hvor de ellers forekommer i beskrivelsen, har de anvendte udtryk 25 følgende betydning.
Udtrykket "lavere alkyl" omfatter ligekædede og forgrenede grupper med op til 6 carbonatomer, fortrinsvis ikke mere end 4 carbonatomer, og eksemplificeres ved sådanne grupper som methyl, ethyl, propyl, isopropyl, butyl, sek.-30 butyl, tert.butyl, amyl, isoamyl og hexyl.
Udtrykket "halogen" omfatter chlor, fluor, brom og iod.
Eksempler på farmaceutisk acceptable metalkationer er natrium, kalium, calcium, magnesium, zink, aluminium, 35 kobber og hydrater deraf.
7-Benzoylmethylindolin-2-onerne med formlen
DK 155936 B
3
0=C H
β n der anvendes som udgangsforbindelser, kan fremstilles ved 10 gængse metoder, f.eks. som beskrevet i de ovennvænte US--patentskrifter nr. 4.045.576 og nr. 4.221.716.
Generelt har stærke antiinflammatoriske lægemidler hidtil vist sig at give alvorlige bivirkninger i form af blødning og sårdannelse i mavesækken, når de indgives oralt 15 til dyr i en mængde i det effektive område. Forbindelserne fremstillet ifølge opfindelsen har vist sig at have den fordel, at der observeres en lavere hyppighed af irritation af mavesækken, når de indgives i en mængde i det effektive område for at formindske inflammation, i sammenligning med 20 indomethacin og 2-amino-3-benzoylphenyleddikesyrer og deres derivater, der er beskrevet i US-patentskrift nr. 4.045.576.
For eksempel viser forbindelsen fremstillet ifølge eksempel 2, natrium-2-amino-3-(4-chlorbenzoyl)-5-methylphenylacetat, sig at være ca. 2 gange så virksom som indomethacin og natri-25 um-2-amino-3-benzoylphenylacetat, men udviser ca. 1/4 af indomethacins irriterende virkning på mavesækken og ca. 1/2 af natrium-2-amino-3-benzoylphenylacetats irriterende virkning på mavesækken. Forbindelsen fremstillet ifølge eksempel 2 viser sig at være ca. 1/2 gang så virksom som natrium-2-30 -amino-3-(4-chlorbenzoyl)-5-fluorphenylacetat, men udviser overraskende ca. 1/4 af denne forbindelses irriterende virkning på mavesækken.
Den antiinflammatoriske virkning demonstreres hos laboratoriedyr under anvendelse af en modifikation af "Evans 35 Blue-Carageenan Pleural Effusion Assay" ifølge L.F. Sancilio, J. Pharmacol. Exp. Ther. 168. 199-204 (1969).
4 I
DK 155936B
Den gastriske toksicitet bestemmes ved en modifikation af metoden ifølge Tsukada et al., Arzneim. Forsch. 28, 428-438 (1978).
Forbindelserne fremstillet ifølge opfindelsen virker 5 også som analgetika som bestemt ved en modifikation af metoden ifølge Collier et al., Brit. J. Pharmacol. Chemother.
32, 295-310 (1968).
Forbindelserne fremstillet ifølge opfindelsen kan indgives på en hvilken som helst af forskellige måder, f.eks.
10 oralt som i kapsler eller tabletter, parenteralt i form af sterile opløsninger eller suspensioner og i nogle tilfælde intravenøst i form af sterile opløsninger. Ved fremstillingen af præparater af forbindelserne inkorporeres den aktive bestanddel i en egnet bærer, f.eks. en farmaceutisk bærer.
15 Egnede farmaceutiske bærestoffer, der kan anvendes til fremstilling af præparaterne, er f.eks. stivelse, gelatine, glucose, magnesiumcarbonat, lactose og malt. Flydende præparater fremstilles ved hjælp af egnede flydende farmaceutiske bærestoffer, f.eks. ethylalkohol, propylenglycol, 20 glycerol og glucosesirup.
De farmakologisk aktive forbindelser kan fordelagtigt anvendes i en enhedsdosering på fra 0,1 til 150 mg. Enhedsdosen kan indgives én gang dagligt eller i flerdobbelte eller delte daglige doser. Den daglige dosis kan variere 25 fra 0,3 til 450 mg. 5 til 25 mg synes at være optimalt pr. enhedsdosis.
Det er kun nødvendigt, at den aktive bestanddel udgør en effektiv mængde, dvs. således at der fås en passende effektiv dosering svarende til den anvendte doseringsform.
30 De nøjagtige individuelle doseringer samt de daglige doser vil naturligvis blive fastlagt ifølge gængse medicinske principper af en læge eller dyrlæge.
De her omhandlede virksomme stoffer kan kombineres med andre farmakologisk aktive midler eller med puffere, 35 antacida eller lignende til indgivelse, og andelen af den aktive bestanddel i præparatet kan varieres inden for vide
DK 155936 B
5 grænser.
Fremstillingen af forbindelserne ifølge opfindelsen illustreres nærmere i de følgende eksempler.
5 Eksempel 1
Fremstilling af natrium-2-amino-3-(4-fluorbenzoyl)--5-methylphenylacetat-monohydrat.
En blanding af 8,0 g (0,03 mol) 7-(4-fluorbenzoyl)--5-methylindolin-2-on i 120 ml 3N natriumhydroxid opvarmes 10 under tilbagesvaling i 16 timer. Efter fortynding med vand til 300 ml titreres opløsningen ved en temperatur på 50°C med koncentreret saltsyre til en pH-værdi på 8,2. Den fremkomne orange opløsning filtreres, og det fremkomne filtrat afkøles til 5°C og gøres surt til en pH-værdi på 4,5 med 15 iseddike. Det fremkomne gule faste stof fraskilles og vaskes med vand og opløses derefter i methylenchlorid. Der tilsættes vand, og blandingen titreres med fortyndet na-triumhydrogencarbonatopløsning, indtil der bibeholdes en pH-værdi på 7,0. Det vandige lag fraskilles og koncentreres 20 ved at fjerne vandet ved azeotrop destillation med absolut ethylalkohol. Det fremkomne gule pulver opløses i isopro-pylalkohol, og der tilsættes 1 ml vand. Efter henstand af blandingen i 3 dage fraskilles det fremkomne gule faste stof og tørres ved 25°C under højvakuum i 2 dage, hvorved 25 der fås 1,6 g (et udbytte på 16,5%) af titelforbindelsen som et gult pulver med et smeltepunkt på 140-160°C.
Analyse for C16H13FNC>3Na, H20: C% H% N% beregnet: 58,72 4,62 4,28 30 fundet: 58,71 4,68 4,26
Eksempel 2
Fremstilling af natrium-2-amino-3-(4-chlorbenzoyl)--5-methylphenylacetat.
35 Ved proceduren ifølge eksempel 1 giver en blan ding af 11,5 g (0,04 mol) 7-(4-chlorbenzoyl)-5-methylindo-
DK 155936 B
6 lin-2-on og 160 ml 3N natriumhydroxid efter omkrystallisation fra vand 2,5 g (18%) af titelforbindelsen som orange nåle med smp. 262°C.
Analyse for C^gH^ClNO^Na: 5 C% H% N% beregnet: 59,00 4,02 4,30 fundet: 58,82 4,09 4,32
Eksempel 3 10 Fremstilling af natrium-2-amino-3-(2,4-dichlor- benzoyl)-5-methylphenylacetat.
Ved proceduren ifølge eksempel 1 giver en blanding af 7-(2,4-dichlorbenzoyl)-5-methylindolin-2-on og 3N natriumhydroxid ovennævnte forbindelse.
15
Eksempel 4
Fremstilling af natrium-2-amino-3-(2,3,5-trichlor-benzoyl)-6-methylphenylacetat.
Ved proceduren ifølge eksempel 1 giver en blan-20 ding af 7-(2,3,5-trichlorbenzoyl)-4-methylindolin-2-on og 3N natriumhydroxid ovennævnte forbindelse.
Eksempel 5
Fremstilling af natrium-2-amino-3-(4-chlorbenzoyl)-25 -4-methylphenylacetat.
Ved proceduren ifølge eksempel 1 giver en blanding af 4-chlorbenzoyl-6-methylindolin-2-on og 3N natriumhydroxid ovennævnte forbindelse.
I det følgende gives eksempler på præparater af de 30 her omhandlede forbindelser.
7
DK 155936B
O
'1. Kapsler
Der fremstilles kapsler med 5, 25 og 50 mg aktiv bestanddel pr. kapsel. Ved de højere mængder af aktiv bestanddel kan mængden af lactose ændres.
5 Typisk blanding til kapsler Pr. kapsel, mg aktiv bestanddel 5,0 lactose 296,7 stivelse 129,0 magnesiumstearat 4,3 10 i alt 435,0 mg
Andre kapselpræparater har fortrinsvis en højere dosis af aktiv bestanddel og har følgende sammensætning: Bestanddele Pr. kapsel, mg aktiv bestanddel 25,0 15 lactose 306,5 stivelse 99,2 magnesiumstearat 4,3 i alt 435,0 mg I hvert enkelt tilfælde blandes den valgte aktive 20 bestanddel ensartet med lactose, stivelse og magnesiumstearat, og blandingen fyldes i kapsler.
2. Tabletter
Et typisk præparat til tabletter indeholdende 5,0 mg aktiv bestanddel pr. tablet angives i det følgende.
25 Præparatet kan anvendes med andre styrker af aktiv bestanddel ved at ændre mængden af dicalciumphosphat.
Pr. tablet, mg (1) aktiv bestanddel 5,0 (2) majsstivelse 13,6 30 (3) majsstivelse (pasta) 3,4 (4) lactose 79,2 (5) dicalciumphosphat 68,0 (6) calciumstearat 0,9 i alt 170,1 mg oc 1, 2, 4 og 5 blandes ensartet. 3 præpareres som en 10%'s pasta i vand. Blandingen granuleres med stivelses-
. DK 155936 B
8 pasta, og den våde masse passeres gennem en 8 mesh sigte.
Det våde granulat tørres og sigtes gennem en 12 mesh sigte. Det tørrede granulat blandes med calciumstearat og presses.
5 3. Injicerbar 2%*s steril opløsning.
_ 3
Pr. cm aktiv bestanddel 20 mg konserveringsmiddel, f.eks.
chlorbutanol 0,5% (vægt/vol.) vand til injektionsbrug q.s.
Opløsningen fremstilles, klares ved filtrering, fyldes i ampuller, forsegles og autoklaveres.
Claims (1)
- DK 155936B O Analogifremgangsmåde til fremstilling af 2-amino--3-(halogenbenzoyl)-methylphenyleddikesyrer eller alkylestere eller metalsalte deraf med formlen I 5 ^^.CHaCOOR eHa-KjT c=o & " hvori 15. er valgt blandt hydrogen, lavere alkyl og en farmaceutisk acceptabel metalkation, Y betyder halogen, og n betyder et helt tal fra 1 til 3, kendetegnet ved, at en 7-benzoylmethylindolin-20 -2-on med formlen 0=C H éi (YJ n hvori Y og n har den ovenfor angivne betydning, 30 hydrolyseres i vandig basisk opløsning til dannelse af et salt af en syre med formlen I, der eventuelt omsættes med en syre til dannelse af en fri syre med formlen I, hvorefter denne frie syre eventuelt omdannes til et metalsalt deraf, som eventuelt omsættes i et egnet opløsningsmiddel 35 med et lavere alkylhalogenid til dannelse af en alkylester med formlen I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23453181A | 1981-02-17 | 1981-02-17 | |
US23453181 | 1981-02-17 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK67382A DK67382A (da) | 1982-08-18 |
DK155936B true DK155936B (da) | 1989-06-05 |
DK155936C DK155936C (da) | 1989-11-06 |
Family
ID=22881752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK067382A DK155936C (da) | 1981-02-17 | 1982-02-16 | Analogifremgangsmaade til fremstilling af 2-amino-3-(halogenbenzoyl)-methylphenyleddikesyrer eller alkylestere eller metalsalte deraf |
Country Status (32)
Country | Link |
---|---|
JP (1) | JPS57149256A (da) |
KR (1) | KR880002289B1 (da) |
AT (1) | AT387213B (da) |
AU (1) | AU7950382A (da) |
BE (1) | BE892156A (da) |
CA (1) | CA1173852A (da) |
CH (1) | CH651294A5 (da) |
DE (1) | DE3204854C2 (da) |
DK (1) | DK155936C (da) |
EG (1) | EG15798A (da) |
ES (1) | ES509622A0 (da) |
FI (1) | FI73970C (da) |
FR (1) | FR2499981B1 (da) |
GB (1) | GB2093027B (da) |
GR (1) | GR76516B (da) |
HK (1) | HK90384A (da) |
HU (1) | HU187644B (da) |
IE (1) | IE52289B1 (da) |
IL (1) | IL64724A0 (da) |
IT (1) | IT1157001B (da) |
KE (1) | KE3454A (da) |
LU (1) | LU83928A1 (da) |
MY (1) | MY8500908A (da) |
NL (1) | NL8200607A (da) |
NO (1) | NO160133C (da) |
NZ (1) | NZ199745A (da) |
PL (1) | PL139815B1 (da) |
PT (1) | PT74441B (da) |
SE (1) | SE453387B (da) |
SG (1) | SG68584G (da) |
YU (1) | YU44333B (da) |
ZA (1) | ZA82697B (da) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683242A (en) * | 1985-10-28 | 1987-07-28 | A. H. Robins Company, Incorporated | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters |
US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
US6034266A (en) * | 1996-03-11 | 2000-03-07 | Fundacao Oswaldo Cruz-Fiocruz | Gem-difluoro derivative of phenylacetamide and phenylacetic acid and their pharmaceutical uses |
BR9600975A (pt) * | 1996-03-11 | 1997-12-30 | Fundacao Oswaldo Cruz | Derivados do ácido gem-difluorfenilacético e de gem-difluorfenilacetamida processo de sua preparação e suas aplicações farmacêuticas |
AR030345A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes relacionados con angiogenesis |
AR030346A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico |
AU2002247284A1 (en) | 2001-04-02 | 2002-10-15 | Alcon, Inc. | Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac |
TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1226344A (da) * | 1967-07-31 | 1971-03-24 | ||
US3997368A (en) * | 1975-06-24 | 1976-12-14 | Bell Telephone Laboratories, Incorporated | Elimination of stacking faults in silicon devices: a gettering process |
CH577461A5 (da) * | 1975-08-13 | 1976-07-15 | Robins Co Inc A H | |
FR2366015A1 (fr) * | 1975-11-05 | 1978-04-28 | Robins Co Inc A H | Nouveaux acides amino-2 benzoyl-3 (5 et 6) phenylacetiques et leurs esters et sels de metaux alcalins, utiles notamment comme anti-inflammatoires, et leur procede de preparation |
IL61945A (en) * | 1980-02-19 | 1984-09-30 | Robins Co Inc A H | 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them |
-
1982
- 1982-01-07 IL IL64724A patent/IL64724A0/xx not_active IP Right Cessation
- 1982-01-14 AU AU79503/82A patent/AU7950382A/en not_active Abandoned
- 1982-01-24 EG EG8228A patent/EG15798A/xx active
- 1982-02-01 JP JP57014710A patent/JPS57149256A/ja active Granted
- 1982-02-03 ZA ZA82697A patent/ZA82697B/xx unknown
- 1982-02-05 AT AT0043382A patent/AT387213B/de not_active IP Right Cessation
- 1982-02-08 FI FI820392A patent/FI73970C/fi not_active IP Right Cessation
- 1982-02-09 LU LU83928A patent/LU83928A1/fr unknown
- 1982-02-09 CH CH791/82A patent/CH651294A5/fr not_active IP Right Cessation
- 1982-02-10 IT IT67152/82A patent/IT1157001B/it active
- 1982-02-11 DE DE3204854A patent/DE3204854C2/de not_active Expired - Fee Related
- 1982-02-12 GB GB8204137A patent/GB2093027B/en not_active Expired
- 1982-02-15 IE IE310/82A patent/IE52289B1/en not_active IP Right Cessation
- 1982-02-15 GR GR67320A patent/GR76516B/el unknown
- 1982-02-15 SE SE8200891A patent/SE453387B/sv unknown
- 1982-02-15 YU YU325/82A patent/YU44333B/xx unknown
- 1982-02-16 HU HU82464A patent/HU187644B/hu unknown
- 1982-02-16 NO NO820468A patent/NO160133C/no unknown
- 1982-02-16 DK DK067382A patent/DK155936C/da not_active IP Right Cessation
- 1982-02-16 NL NL8200607A patent/NL8200607A/nl not_active Application Discontinuation
- 1982-02-16 FR FR8202507A patent/FR2499981B1/fr not_active Expired
- 1982-02-16 PT PT74441A patent/PT74441B/pt not_active IP Right Cessation
- 1982-02-16 BE BE0/207327A patent/BE892156A/fr not_active IP Right Cessation
- 1982-02-16 CA CA000396392A patent/CA1173852A/en not_active Expired
- 1982-02-16 KR KR8200673A patent/KR880002289B1/ko active
- 1982-02-16 PL PL1982235095A patent/PL139815B1/pl unknown
- 1982-02-16 ES ES509622A patent/ES509622A0/es active Granted
- 1982-02-16 NZ NZ199745A patent/NZ199745A/en unknown
-
1984
- 1984-09-17 KE KE3454A patent/KE3454A/xx unknown
- 1984-09-21 SG SG68584A patent/SG68584G/en unknown
- 1984-11-15 HK HK903/84A patent/HK90384A/xx unknown
-
1985
- 1985-12-30 MY MY908/85A patent/MY8500908A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4126635A (en) | 2-amino-3-(5- and 6-)benzoylphenylacetic acids, esters and metal salts thereof | |
JP2919030B2 (ja) | キノン誘導体 | |
US3517051A (en) | Phenoxy substituted phenylacetic acids | |
US3957850A (en) | Phenylacetic acid derivatives | |
US4503073A (en) | 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids | |
IL23152A (en) | Alkanoic acids are converted by aryl groups | |
DK155936B (da) | Analogifremgangsmaade til fremstilling af 2-amino-3-(halogenbenzoyl)-methylphenyleddikesyrer eller alkylestere eller metalsalte deraf | |
DE1937477A1 (de) | Neue 1-Phenoxy-2-hydroxy-3-cycloalkylaminopropane und Verfahren zu ihrer Herstellung | |
US4254146A (en) | 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters | |
US4760078A (en) | Immunomodulator 1,2-dithiol-3-thione derivative composition, use method and process of producing the same | |
US4000297A (en) | N-p-chlorobenzoyl tryptophane, salts and compositions thereof | |
US4092430A (en) | Antiphlogistic phenylacetohydroxamic acid compositions | |
DK154136B (da) | Analogifremgangsmaade til fremstilling af 2-amino-3-benzoylphenylacetamider | |
US4198431A (en) | Alkyl N-(3-trifluoromethylphenyl)-anthranilate | |
US3962435A (en) | Combination of oxytetracycline and 2,4-diamino-5-(3-alkoxy-4,5-methylenedioxybenzyl)pyrimidine | |
US3644424A (en) | Glyceryl acetylsalicylate and its analgesic anti-inflammatory use | |
US3923996A (en) | 3-Substituted-oxindoles in compositions and methods of treating obesity | |
US3518297A (en) | N-(acetylsalicyl)anthranilic acid compounds | |
CA1147746A (en) | 2-amino-3-(alkylthiobenzoyl)phenylacetic acids | |
US4397862A (en) | Gastrointestinal sparing thioester drugs | |
US3772378A (en) | 7-oxo-benzocycloheptene acetic acids | |
US3993761A (en) | Antibacterial compositions | |
US3772341A (en) | Substituted2,5-diphenyl-3,4,6-trihydroxy-delta2,4-hexadienoic acid lactones(1,4) | |
US3891699A (en) | Biphenylenealkanoic acids | |
IL23268A (en) | Anti-inflammatory preparations containing the 4-phenyl-alpha-methyl acid acetic phenyl acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PBP | Patent lapsed |